Mednax, Inc (NYSE:MD) has earned an average recommendation of “Hold” from the fifteen research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $56.63.

A number of brokerages have recently commented on MD. Jefferies Group LLC reissued a “hold” rating and set a $46.00 price objective on shares of Mednax in a research report on Tuesday. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. KeyCorp raised shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price on the stock in a report on Sunday, September 17th. Finally, Mizuho reiterated a “neutral” rating and issued a $48.00 price target (down previously from $62.00) on shares of Mednax in a research note on Tuesday, August 1st.

In related news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now directly owns 35,569 shares in the company, valued at approximately $1,524,131.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Mednax by 0.3% during the second quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock worth $498,505,000 after buying an additional 28,155 shares during the period. Vanguard Group Inc. lifted its stake in Mednax by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after buying an additional 38,645 shares during the last quarter. FMR LLC lifted its stake in Mednax by 1.3% in the first quarter. FMR LLC now owns 5,313,581 shares of the company’s stock valued at $368,656,000 after buying an additional 68,581 shares during the last quarter. Longview Partners Guernsey LTD lifted its stake in Mednax by 10.3% in the second quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock valued at $303,267,000 after buying an additional 467,845 shares during the last quarter. Finally, State Street Corp lifted its stake in Mednax by 2.2% in the first quarter. State Street Corp now owns 2,943,797 shares of the company’s stock valued at $204,246,000 after buying an additional 62,812 shares during the last quarter.

Shares of Mednax (NYSE:MD) traded up 1.17% during trading on Friday, reaching $44.80. 1,699,573 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $42.97 and a 200 day moving average price of $54.59. The company has a market capitalization of $4.13 billion, a P/E ratio of 14.27 and a beta of 0.37. Mednax has a 12-month low of $40.78 and a 12-month high of $72.13.

Mednax (NYSE:MD) last issued its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company had revenue of $843.00 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter last year, the company posted $1.03 EPS. The firm’s revenue was up 9.2% compared to the same quarter last year. Equities analysts expect that Mednax will post $3.31 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/03/mednax-inc-md-receives-56-63-average-price-target-from-analysts.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.